CN108070651A - 一种评估crc复发风险的诊断分析/预后分析方法 - Google Patents

一种评估crc复发风险的诊断分析/预后分析方法 Download PDF

Info

Publication number
CN108070651A
CN108070651A CN201610969977.3A CN201610969977A CN108070651A CN 108070651 A CN108070651 A CN 108070651A CN 201610969977 A CN201610969977 A CN 201610969977A CN 108070651 A CN108070651 A CN 108070651A
Authority
CN
China
Prior art keywords
risks
recurrence
assessing
analysis method
crc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610969977.3A
Other languages
English (en)
Inventor
杨义力
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Ankang Alliance Medical Technology Co Ltd
Original Assignee
Suzhou Ankang Alliance Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Ankang Alliance Medical Technology Co Ltd filed Critical Suzhou Ankang Alliance Medical Technology Co Ltd
Priority to CN201610969977.3A priority Critical patent/CN108070651A/zh
Publication of CN108070651A publication Critical patent/CN108070651A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

一种评估CRC复发风险的诊断分析/预后分析方法，包括FGF18纤维母细胞生长因子18，PGR孕酮受体,ERBB2 v‑erb‑b2成红细胞的白血病病毒性致癌基因同系物2，神经/恶性胶质瘤衍生的致癌基因同系物（禽鸟）,MKI67增殖标记Ki‑67,BCL2 B‑细胞慢性淋巴细胞性白血病/淋巴瘤2,INHBA人类抑制素，beta A。本发明精确地判定活组织检查或者手术切除的肿瘤组织是否的确是结肠直肠癌，以及哪些患者癌症复发的几率高，然后根据判定结果选择根据患者肿瘤基因构造量身定制最有效的方案进行化学疗法。

Description

一种评估CRC复发风险的诊断分析/预后分析方法
本发明涉及医疗评估方面，尤其涉及一种评估CRC复发风险的诊断分析/预后分析方法。
背景技术
直肠结肠癌（简称CRC）是最常见的恶性肿瘤之一，全世界每年新增120万新病例，每年约有70万人死亡。在发达国家CRC的死亡率和发病率一直在下降，这主要归功于早期筛查，但在发展中国家(包括中国)CRC的发病率处于增长趋势。在中国CRC的发病率在过去数十年里每年上升近4%1，2。值得注意的是，CRC患者的生存几率主要取决于诊断时肿瘤处于哪个阶段，在美国，所有CRC患者中只有40%的患者是在病灶处于原位时诊断出来的1，5。约有50%处于晚期的患者在得出最初诊断后五年内死亡，大多数死亡原因都是由于肿瘤转移，尤其是肝转移。因此，早期诊断和对已经转移的肿瘤新颖有效的治疗对于改善CRC患者的健康状况非常关键。
本发明就是本着方便使用人员，让使用人员可方便操作的目的，应运而生。
发明内容
本发明是通过以下技术方案实现：
一种评估CRC复发风险的诊断分析/预后分析方法，包括FGF18纤维母细胞生长因子18，PGR孕酮受体, ERBB2 v-erb-b2成红细胞的白血病病毒性致癌基因同系物2，神经/恶性胶质瘤衍生的致癌基因同系物（禽鸟）, MKI67增殖标记Ki-67, BCL2 B-细胞慢性淋巴细胞性白血病/淋巴瘤2, INHBA人类抑制素，beta A
作为本发明的进一步优化方案，所述使用了149种主要浸润性乳腺肿瘤完整的人类基因组基因表达谱。
作为本发明的进一步优化方案，所述通过评估七种概率性分类器（包括复合协变量、线性判别、1-近邻法、3-近邻法、最近图心、支持向量机以及贝叶斯复合协变量算法）改进乳腺癌风险分类模型。
与现有的技术相比，本发明的有益效果是：本发明精确地判定活组织检查或者手术切除的肿瘤组织是否的确是结肠直肠癌，以及哪些患者癌症复发的几率高，然后根据判定结果选择根据患者肿瘤基因构造量身定制最有效的方案进行化学疗法。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白，以下结合实施例，对本发明进行进一步详细说明。应当理解，此处所描述的具体实施例仅仅用以解释本发明，并不用于限定本发明。
一种评估CRC复发风险的诊断分析/预后分析方法，包括FGF18纤维母细胞生长因子18， PGR孕酮受体, ERBB2 v-erb-b2成红细胞的白血病病毒性致癌基因同系物2，神经/恶性胶质瘤衍生的致癌基因同系物（禽鸟）, MKI67增殖标记Ki-67, BCL2 B-细胞慢性淋巴细胞性白血病/淋巴瘤2, INHBA人类抑制素，beta A
作为本发明的进一步优化方案，所述使用了149种主要浸润性乳腺肿瘤完整的人类基因组基因表达谱。
作为本发明的进一步优化方案，所述通过评估七种概率性分类器（包括复合协变量、线性判别、1-近邻法、3-近邻法、最近图心、支持向量机以及贝叶斯复合协变量算法）改进乳腺癌风险分类模型。
以上所述仅为本发明的较佳实施例而已，并不用以限制本发明，凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等，均应包含在本发明的保护范围之内。

Claims (3)

1.一种评估CRC复发风险的诊断分析/预后分析方法，包括FGF18纤维母细胞生长因子18， PGR孕酮受体, ERBB2 v-erb-b2成红细胞的白血病病毒性致癌基因同系物2，神经/恶性胶质瘤衍生的致癌基因同系物（禽鸟）, MKI67增殖标记Ki-67, BCL2 B-细胞慢性淋巴细胞性白血病/淋巴瘤2, INHBA人类抑制素，beta A。
2.根据权利要求1所述的一种评估CRC复发风险的诊断分析/预后分析方法，其特征在于：使用了149种主要浸润性乳腺肿瘤完整的人类基因组基因表达谱。
3.根据权利要求1所述的一种评估CRC复发风险的诊断分析/预后分析方法，其特征在于：通过评估七种概率性分类器（包括复合协变量、线性判别、1-近邻法、3-近邻法、最近图心、支持向量机以及贝叶斯复合协变量算法）改进乳腺癌风险分类模型。
CN201610969977.3A 2016-11-07 2016-11-07 一种评估crc复发风险的诊断分析/预后分析方法 Pending CN108070651A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610969977.3A CN108070651A (zh) 2016-11-07 2016-11-07 一种评估crc复发风险的诊断分析/预后分析方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610969977.3A CN108070651A (zh) 2016-11-07 2016-11-07 一种评估crc复发风险的诊断分析/预后分析方法

Publications (1)

Publication Number Publication Date
CN108070651A true CN108070651A (zh) 2018-05-25

Family

ID=62153144

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610969977.3A Pending CN108070651A (zh) 2016-11-07 2016-11-07 一种评估crc复发风险的诊断分析/预后分析方法

Country Status (1)

Country Link
CN (1) CN108070651A (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2631720A1 (en) * 2005-12-09 2007-09-13 The Board Of Trustees Of The University Of Arkansas Antineoplasics activities of ellipticine and its derivatives
US8163896B1 (en) * 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
CN102858985A (zh) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 基因组编辑方法
CN102971001A (zh) * 2009-08-14 2013-03-13 阿勒根公司 使用生长因子再靶向内肽酶治疗癌症的方法
CN103517921A (zh) * 2010-12-21 2014-01-15 Abbvie公司 IL-1-α和-β双特异性双重可变结构域免疫球蛋白及其用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163896B1 (en) * 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
CA2631720A1 (en) * 2005-12-09 2007-09-13 The Board Of Trustees Of The University Of Arkansas Antineoplasics activities of ellipticine and its derivatives
CN102858985A (zh) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 基因组编辑方法
CN102971001A (zh) * 2009-08-14 2013-03-13 阿勒根公司 使用生长因子再靶向内肽酶治疗癌症的方法
CN103517921A (zh) * 2010-12-21 2014-01-15 Abbvie公司 IL-1-α和-β双特异性双重可变结构域免疫球蛋白及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
唐林等: ""miRNA在大肠癌中的作用"", 《癌症进展》 *

Similar Documents

Publication Publication Date Title
Antony et al. Carcinoma ex pleomorphic adenoma: a comprehensive review of clinical, pathological and molecular data
Le et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas
Rigual et al. Photodynamic therapy with 3-(1′-hexyloxyethyl) pyropheophorbide a for cancer of the oral cavity
Lee et al. Breast cancer–specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast
Kunisaki et al. Clinical impact of metastatic lymph node ratio in advanced gastric cancer
CN108949985A (zh) circ-WHSC1作为结直肠癌诊断标志物及其应用
Fu et al. miRNAs as potential biomarkers in early breast cancer detection following mammography
CN108795938A (zh) 肺腺癌外泌体特异miRNA及其靶基因与应用
Kormi et al. New insights into colorectal cancer screening and early detection tests
US10085987B2 (en) MCT protein inhibitor-related prognostic and therapeutic methods
Kamil et al. Association between HER-2/neu over-expression and clinico-pathologic parameters of breast cancer in northern Malaysia
Guastafierro et al. The influence of breast cancer on the distribution of cherry angiomas on the anterior thoracic wall: a case series study
Morikawa et al. The utility of optical instrument “ORALOOK®” in the early detection of high-risk oral mucosal lesions
Ansarin et al. Endoscopic CO2 laser surgery for early glottic cancer in patients who are candidates for radiotherapy: results of a prospective nonrandomized study
Singh-Ranger et al. Current concepts in the non-operative management of rectal cancer after neoadjuvant chemoradiation
Treder et al. Role of neoadjuvant radio-chemotherapy for the treatment of high rectal cancer
Que et al. New strategy for antimetastatic treatment of lung cancer: a hypothesis based on circulating tumour cells
Yu et al. Therapeutic efficacy comparison of two surgical procedures to treat middle thoracic esophageal carcinoma
CN108070651A (zh) 一种评估crc复发风险的诊断分析/预后分析方法
Willett et al. Radiation therapy in stage II and III rectal cancer
CN108815173A (zh) 一种利用光镊装置捕获前列腺癌细胞到药品的方法
Biswas et al. A comparative study of treatment outcome in younger and older patients with locally advanced oral cavity and oropharyngeal cancers treated by chemoradiation
Sarı et al. Treatment results of the Ewing sarcoma of bone and prognostic factors
Tan et al. Breast-Conserving Surgery for Breast Cancer
Plank et al. P2. 11-18 A Comprehensive Lung Cancer Screening Program: 5 Years in Review

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180525

RJ01 Rejection of invention patent application after publication